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" Now this is not the end. It is not even the beginning of 
the end. But it is, perhaps, the end of the beginning”  
Winston Churchill 
  
ABSTRACT 
Asthma is a term that encompasses a disease spectrum with different phenotypes that vary in 
severity and whose common characteristic is airflow limitation. Allergic asthma is the most 
common phenotype of asthma and is characterized by allergen induced inflammatory 
responses, airway hyperresponsiveness (AHR), and remodeling. The limitations of current 
treatment together with the prospect of curative therapies set the incentive for identifying novel 
targets for asthma treatment. The epithelium-derived cytokine interleukin-33 (IL-33) and its 
receptor ST2 are implicated in the initiation and progression of asthma by several genetic and 
experimental studies. This thesis investigates the role of the IL-33/ST2 pathway in asthma 
development, exacerbation and treatment, using mouse models of asthma.  
In paper I, we investigated the role of IL-33/ST2 signaling in promoting allergen-induced 
AHR, airway inflammation, and remodeling in a mouse model of asthma, in which wild-type 
and ST2-/- mice were exposed to intranasal instillations of house dust mite (HDM) extract. We 
revealed that ST2-dependent signaling is important for the development of AHR in the 
peripheral lung compartment and for the development of inflammatory responses including 
airway eosinophilia, induction of allergen-specific IgE, inflammation and goblet cell 
hyperplasia in the peripheral airways, and production of the cytokines IL-5, IL-13 and IL-33. 
In paper II, we tested the hypothesis that IL-33/ST2-dependent mast cell responses 
contribute to the development of AHR and airway inflammation, using a model where the 
lungs of mast cell deficient mice were engrafted with either wild-type or ST2-/- bone marrow 
derived mast cells, and subsequently exposed to HDM. Unexpectedly, we discovered a 
protective role for ST2-dependent mast cell responses in the development of AHR located in 
the peripheral lung. This protective effect appeared to be independent of airway inflammation 
but was associated with elevated levels of PGE2, which has a bronchoprotective role in asthma.    
In paper III, we explored the potential of IL-33 to exacerbate allergen-induced asthma 
responses by exposing OVA-sensitized mice to IL-33 before each antigen challenge. We found 
that IL-33 acted cooperatively with antigen to aggravate AHR, remodeling and several 
inflammatory responses, including a substantial potentiation of antigen-specific IgE antibody 
production, increased mast cell activity, elevated levels of the TH2 cytokines IL-4, IL-5 and IL-
13, and accumulation of inflammatory cells in the airways and lung tissue, including 
expansion of the ILC2 population in the lungs.     
In paper IV, we evaluated the effects of vaccination against IL-33 in a mouse model of 
HDM-induced asthma. The vaccine comprised a recombinant IL-33 protein modified to induce 
immunological memory response, while reducing its cytokine activity. Vaccination against IL-
33 induced high titers of anti-IL-33 IgG antibodies, and attenuated several HDM-induced 
responses including AHR, airway eosinophilia, accumulation of inflammatory cells in the 
airways, and the levels of inflammatory cytokines including IL-25, IL-33 and TSLP.  
In conclusion, the work presented in this thesis provides further evidence and new insights 
into the importance of the IL-33/ST2 pathway in the development of asthma. The studies of 
this thesis identify an important role for this pathway in the regulation of AHR in the 
peripheral lung compartment, a protective role on AHR mediated by mast cells, and a role in 
asthma exacerbations associated with the expansion of the ILC2 population. Finally, we 
demonstrate that targeting the IL-33/ST2 pathway by vaccination against IL-33 has the 
potential to be an effective therapeutic tool for treating asthma.  
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1 INTRODUCTION 
1.1 ASTHMA 
Asthma is a common disease of the lungs affecting more than 300 million people worldwide 
and is associated with substantial morbidity and economic burden [1]. The definition of 
asthma is controversial but the condition is usually described as a chronic disorder of the 
airways that is characterized by variable symptoms of reversible airflow obstruction, airway 
hyperresponsiveness (AHR) and underlying inflammation. The clinical presentation varies 
depending on severity, but manifests usually as recurrent episodes of wheezing, chest 
tightness, shortness of breath and cough [2]. These episodes can be triggered by exposures to 
various environmental stimuli such as allergens, and infectious agents, particularly viruses.  
Traditionally, two major forms of asthma have been defined in the clinic; allergic asthma, 
which usually has an early onset, and non-allergic (intrinsic) asthma that often manifests later 
in life. Most children and nearly half of adults with asthma have allergic asthma that 
coincides with allergic sensitization characterized by the presence of TH2 inflammation. 
However, it is increasingly recognized that asthma is not a single disease but rather an 
umbrella term encompassing a spectrum of diseases, where the same observable 
characteristic (phenotype) can arise as a consequence of different underlying cellular and 
molecular mechanisms (endotypes) [2, 3]. This has in turn awakened an interest for 
identifying pathophysiological mechanisms and biomarkers that distinguish subsets of 
patients based on various aspects including asthma symptoms, relative involvement of the 
large and small airways, innate and adaptive immune responses to allergens, susceptibility to 
viral infections leading to exacerbations, and response to treatment.  
In general, targeting components of TH2 inflammation in allergic asthma with selective 
therapies, including targeting of individual TH2 cytokines, has so far been disappointing and 
therapy still mostly relies on bronchodilators and corticosteroids that do not affect the 
underlying dysregulated immune response. In light of this, a new case is made that asthma 
originates in the airways themselves and involves defective structural and functional behavior 
of the epithelium in response to environmental insults that creates a chronic wound scenario 
involving tissue injury and impaired repair [4]. Specifically, it has been proposed that 
aberrant interactions between epithelial cells and underlying resident cells are fundamental 
for the development of asthma [4, 5]. In this setting there is a particular interest in the 
epithelium-derived cytokine IL-33 and its receptor ST2, mainly due to the strong association 
to asthma risk in genome wide association studies [6-8]. The relevance of this association has 
been highlighted in several studies in asthma patients and experimental models [9-11]. 
Together, these finding implicate the IL-33/ST2 pathway as a promising target for novel 
treatment strategies.  
This thesis investigates the role of the IL-33/ST2 pathway in asthma development, 
exacerbation and treatment. More specifically, modulation of this pathway is investigated in 
the context of allergen-induced asthma in mouse models where the cardinal features of 
asthma including airway inflammation, AHR and remodeling are evaluated.  
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The profile of airway inflammation varies depending on the asthma subtype. The most 
common inflammatory profile of asthma is associated with eosinophilia and type 2 
inflammation. However, some patients show a neutrophil-predominant inflammation with an 
absence of TH2 cytokines. This type of inflammation is characteristic of patients with late-
onset and more severe forms of asthma with less reversible airway obstruction and a mixed 
TH1 and TH17 cytokine environment [12-14].    
1.1.1 Type 2 inflammation in asthma  
Type 2 immune responses can be highly appropriate when initiated by for instance helminth 
infections that lead to functional alterations that favor worm expulsion. On the other hand, 
misdirected type 2 responses to harmless allergens can have detrimental effects leading to 
atopic diseases, such as allergy and asthma. Type 2 inflammatory responses in the lungs often 
start in childhood. It is believed that exposure to environmental agents such as respiratory 
virus infections and allergens can initiate pathogenic immune responses, which lead to the 
development of asthma in children who are predisposed because of specific genetic risk 
factors in important regulators of type 2 inflammation (atopy), or because of other 
vulnerabilities [15].  
The type 2 cytokines, including IL-4, IL-5 and IL-13, are highly associated to the 
pathogenesis of asthma, regulating many key responses, including eosinophilia, IgE 
synthesis, bronchoconstriction, and mucus production [16-19]. More specifically, IL-4 is 
involved in the isotype class switching of B cells to the synthesis of IgE antibodies, which 
can be bound to high affinity Fcε receptors (FcεRI) on mast cells and basophils [20]. IL-5 
activates and recruits eosinophils to the lung, where they secrete inflammatory cytokines and 
chemokines [21]. IL-13 can directly affect the airway epithelium and smooth muscle (ASM) 
cells and thereby contribute to AHR, mucus hyperproduction, and in chronic inflammation, to 
airway remodeling [22, 23]. TH2 cells are key players in allergic asthma, as they are major 
producers of these prototypical cytokines [24, 25]. In addition to TH2 cells, it is now 
recognized that group 2 innate lymphoid cells (ILC2s) are an important and earlier source of 
TH2 cytokines, particularly IL-5 and IL-13 [26]. Mast cells are also an important source of 
type 2 cytokines including IL-4, IL-5 and IL-13 [27, 28]. ILC2s seem to secrete very little IL-
4 and the relative importance of TH2 cells, ILC2s, and mast cells in the production of type 2 
cytokines is still unclear [29].  Nevertheless, there seems to be a consensus that upstream 
events in the airway epithelium, involving epithelium derived key regulatory cytokines, such 
as IL-25, IL-33 and thymic stromal lymphopoietin (TSLP), initiate both adaptive and innate 
type 2 responses that lead to increased production of type 2 cytokines [15]. IL-33 regulation 
of these events are further discussed in section 1.6.5 where the current knowledge about IL-
33 from experimental studies are put in the context of type 2 responses identifying potential 
mechanisms by which IL-33 contributes to development of asthma. Central to this thesis are 
the highly IL-33 responsive ILC2s and mast cells, which are described in general in the 
following sections and further in the context of IL-33 responses in section 1.6.5.  
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1.1.1.1 ILC2s  
ILCs are tissue-resident innate cells, which are classified into three different subtypes; ILC1s, 
ILC2s and ILC3s, based on a similar cytokine profile corresponding to the helper T subsets 
TH1, TH2, and TH17, respectively [29]. They are promptly activated by danger signals from 
injured mucosa and thereby maintain mucosal integrity in response to invading pathogens. It 
is becoming increasingly recognized that the phenotype of ILCs is not stable. Indeed, ILCs 
are highly plastic and can change phenotypes under the influence of environmental triggers 
[30].    
The observation that RAG-/- mice, lacking mature T cells and B cells, were still able to 
mount a strong type 2 response challenged the role for TH2 cells in driving type 2 responses 
[31, 32]. This finding suggested that there were pathways independent of the adaptive 
immune system that could induce type 2 responses and led to the identification of a 
previously unrecognized innate cell population, currently termed type 2 lymphoid cells 
(ILC2s) [33]. ILC2s resemble TH2 cells in their capacity to produce type 2 associated 
cytokines but due to the absence of rearranged antigen-specific receptors, their response is not 
antigen-specific [26]. Thus, instead of becoming activated by antigen presentation through 
antigen-presenting cells (APCs), ILC2s respond by sensing danger signals from the tissue 
environment.    
Several cytokines can activate ILC2s including the epithelium derived cytokines IL-25, IL-
33, and TSLP, which have in particular been shown to initiate ILC2 responses [34]. The 
relative importance of these cytokines in activating ILC2s seems to vary depending on the 
experimental setting. Airway challenge of IL-33 receptor deficient (ST2-/-) mice with ragweed 
pollen or ovalbumin suggests that IL-33 is more potent than IL-25 in promoting pulmonary 
ILC2 activation [35]. TSLP was shown to synergize with IL-33 to produce IL-5 and IL-13 in 
a chitin induced model of airway inflammation in mice [36], and ILC2 activation was only 
abolished in the combined absence of IL-25, IL-33, and TSLP signaling [37]. Recently, it was 
reported that mast cell derived IL-2 leads to the expansion of ILC2s in a positive feedback 
loop that is driven by IL-9,  of relevance in driving inflammation in patients with cystic 
fibrosis [38].  In the proposed model, IL-9 produced by IL-33-expanded ILC2s, activates 
mast cells for IL-2 production leading to the expansion of ILC2s that in turn promote TH9 
activation, and the resulting IL-9 production further amplifies the inflammatory loop. 
Additionally, ILC2s have been shown to be activated by leukotrienes [39] and prostaglandins 
[40, 41].  
Mouse models of asthma that use ovalbumin (OVA), house dust mite (HDM), fungal 
allergens, and papain, show that ILC2s increase in number and are the major source of IL-5 
and/or IL-13, particularly in the early phase [26, 42, 43]. Allergens can induce expansion of 
ILC2s, high levels of type 2 cytokines, and significant AHR in mice lacking an adaptive 
immune system [42, 44].   
The role of ILC2s in the airways of patients with allergic asthma has been investigated by 
several studies. An increased frequency of IL-13 producing ILC2s was found in the BALF 
from asthma patients compared to control subjects [45]. Higher levels of ILC2s were 
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observed in sputum of patients with corticosteroid resistant severe asthma compared to 
healthy controls as well as with patients with mild asthma [46]. An increased number of 
ILC2s was also found in sputum of children with severe therapy-resistant asthma compared 
with children without asthma but with lower respiratory tract infections [47].    
1.1.1.2 Mast cells  
Mast cells originate from pluripotent hematopoietic stem cells, which circulate as CD34+ 
precursors in the blood before migrating into tissues where they mature into long-lived 
effector cells [48-50]. As tissue resident cells, mast cells predominantly populate tissues 
facing the external environment such as the skin, intestine and lung [51]. Mast cells are often 
located in close proximity to blood and lymph vessel, and nerves where they can release 
locally or systemically active mediators [52]. In humans, mast cell subtypes are divided based 
on their protease content. MCT store tryptase, while MCCT store both chymase and tryptase in 
their granula [53]. MCT are predominantly found in the lung and intestinal mucosa, whereas 
MCCT appear in the skin and lymph nodes. However, this division is likely an 
oversimplification, as site-specific microenvironment dependent subpopulations of these 
phenotypes exist in the lung [54]. Two types of mast cells are recognized in mice; mucosal 
mast cells (MMCs) and connective tissue mast cells (CTMCs) [55-58]. Mast cell mediators 
are either stored in granules, and can be released immediately during degranulation, or 
synthesized de novo after activation and are released within minutes to hours after activation 
[59, 60]. Accordingly, mast cell mediators can be divided into three groups; 1) preformed 
substances, 2) lipid mediators and 3) cytokines and chemokines [49].    
Mast cells express a variety of receptors associated with innate and adaptive immunity. There 
are a wide range of stimuli that can modulate mast cell responses, including IgE-mediated 
crosslinking of the membrane bound IgE high affinity receptor (FcεRI), which is the most 
well characterized pathway of mast cell activation [61]. Activation of mast cells can also 
occur by specific microbial patterns via Toll like receptors (TLRs) [62, 63], and by the 
epithelial derived cytokines IL-33 and TSLP, via the ST2 and TSLP receptor, respectively 
[64, 65].  
Mast cells and several mast cell derived mediators have been shown to be important during 
the development of allergic airway disease. They are primarily located adjacent to blood 
vessels in the lamina propria of airway mucosa in human airways. In patients with asthma 
mast cells can also be found in proximity to other key structures that are involved in the 
pathophysiology of asthma including the airway epithelium, mucous glands, and airway 
smooth muscle [27, 66, 67]. There exists an extensive crosstalk between mast cells and 
smooth muscle cells as evident from in vitro studies of their interactions. Mast cells have 
been shown to induce differentiation of smooth muscle cells into a more contractile 
phenotype [68]. In turn, smooth muscle cells can enhance mast cell survival and induce 
degranulation [69].  
Increased concentrations of mast cell mediators such as histamine, leukotrienes, proteases and 
prostaglandins can be found in the BALF of aeroallergen challenged patients with allergic 
asthma [70-72]. The rapid release of mast cell mediators by allergen crosslinking of 
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membrane bound IgE results in the early allergic reaction that happens within minutes and 
causes contraction of the airway smooth muscle (bronchoconstriction), vasodilation, 
increased airway permeability and epithelial mucus production leading to airflow 
obstructions. Additionally, these mediators also lead to the late phase response that is 
characterized by inflammatory cell infiltration (by eosinophils, CD4+ T cells, neutrophils, 
mast cells and basophils), and associated with bronchial swelling and AHR. In support of the 
importance of mast cells in these reactions, treatment with anti-IgE antibodies, and histamine 
and leukotriene receptor antagonist, completely inhibits the development of the early phase 
response and in part also the late phase response [73-75].  
1.2 AIRWAY HYPERRESPONSIVENESS  
Airway hyperresponsiveness (AHR) is a consistent and cardinal feature of asthma and is 
defined by an exaggerated response of the airways to narrow or close in response to stimuli 
that would produce little or no effect in healthy individuals [76]. The presence of AHR is 
associated with an increased decline in lung function and the severity with an increased risk 
of exacerbation [77, 78].  
1.2.1 Measurement of AHR 
AHR is usually measured using bronchial provocation tests during which a 
bronchoconstrictive agent is inhaled in increasing doses, which assists in making clinical 
diagnosis of asthma. Spirometry is performed before and after each dose, and a 20% fall in 
FEV1 (forced expiratory volume in one second) is considered a positive reaction and the 
provocative dose that causes this reaction (the PD20) is used to indicate the level of airway 
hyperresponsiveness [76]. The test is considered negative if FEV1 does not fall by at least 
20% with the highest concentration. There are two main groups of bronchoconstrictive agents 
used to measure AHR; those which are thought to act directly on the airway smooth muscle 
receptors to induce bronchoconstriction and those with an indirect bronchoconstrictive effect 
that is mediated by the release of mediators following the primary stimuli [79]. Direct 
challenge tests include agents such as methacholine or histamine and indirect challenge tests 
include mannitol, various allergens and exercise. The traditional determination of AHR using 
spirometric parameters like FEV1 is highly effort dependent, which may pose a problem in 
evaluating some patients including small children as the method requires substantial co-
operation. In contrast, the forced oscillation technique (FOT) is a measure of respiratory 
mechanics that can be acquired employing small-amplitude pressure oscillations 
superimposed on the normal breathing, and therefore is not dependent on performance of 
breathing manoeuvers. 
1.2.2 Mechanisms of AHR 
The mechanisms underlying AHR in asthma is still poorly understood, most likely different 
mechanisms or a combination of these give rise to AHR in different patients [80]. AHR can 
be seen as consisting of two components; the acute and variable AHR, which is closely 
associated with an episodic increase in airway inflammation due to environmental factors 
such as allergen exposure, and a baseline AHR, which is persistent and presumably caused by 
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airway remodeling due to chronic airway inflammation [81]. Although, airway inflammation, 
structural remodeling and functional changes in the airway smooth muscle likely contribute 
to AHR, the mechanisms that link these changes are not clear.  
There is a positive correlation between the severity of AHR and the number of eosinophils in 
sputum [82] , as well as mast cells in the airways of patients with asthma [67], which suggests 
that these factors may contribute to the severity of AHR. Since bronchoconstriction is 
mediated by airway smooth muscle (ASM) surrounding the airway, the contractility of ASM 
has been implicated as a principal cause of AHR. In support of this notion, a study employing 
gene expression profiling of ASM revealed several genes that differentiated asthmatic and 
non-asthmatic patients and related to the severity of AHR [83]. Moreover, the expression of 
contractile proteins such as α-smooth muscle actin in ASM from asthma patients correlates 
with AHR severity [84]. ASM responsiveness seems to be regulated by several pro-
inflammatory mediators including IL-4, IL-13 and tumor necrosis factor-α (TNF-α), 
potentially through effects on calcium signaling [85]. Interestingly, the number of mast cells 
within the ASM correlates with AHR severity in asthma [86, 87] and mast cell mediators 
such as histamine and prostaglandin D2 (PGD2) may contribute to increased basal tone of the 
ASM [88, 89]. Furthermore, AHR correlates with several changes related to structural airway 
remodeling [90-92].   
1.3 AIRWAY REMODELING 
Airway remodeling in asthma refers to the pathological changes that occur in the airway 
epithelium and submucosa which are associated with an irreversible loss of function that 
tracks from childhood to adulthood [93]. Epithelial changes include goblet cell metaplasia, 
hyperplasia and increased mucin accumulation. Submucosal changes include subepithelial 
fibrosis (characterized by increased deposition of collagen type I, III and V beneath the 
basement membrane), increased volume of submucosal gland cells, smooth muscle cell 
hypertrophy and hyperplasia and increased number of blood vessels [94-96]. These structural 
changes are considered to predispose to asthma exacerbations due to narrowed airways at 
baseline and increased sensitivity to inhaled exacerbants such as viruses or allergens [97]. 
The relationship between airway inflammation, remodeling and AHR remains controversial. 
Human and animal studies have for a long time supported the hypothesis that chronic 
inflammation may drive remodeling in patients with asthma. This theory has mainly been 
supported by the finding that steroid treatment in patients with asthma in addition to reducing 
airway inflammation also has beneficial effects on airway remodeling [92, 98, 99]. Although 
the classical type 2 cytokines, IL-4, IL-5, IL-9 and IL-13, have prominent functions in 
directing the production of allergen-specific IgE, recruitment of eosinophils or development 
of AHR; their impact on airway remodeling is still unclear. In fact, IL-13 seems to be the 
only type 2 cytokine with profound effects on airway structural cells, as it induces mucin 
expression and mucus metaplasia in both epithelial cells and submucosal glands, and also has 
a crucial role in goblet cell hyperplasia and metaplasia [100, 101].   
However, an increasing amount of studies suggest that airway remodeling, rather than a 
secondary event to inflammation, can evolve as a primary event initiated early in life in the 
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absence of any apparent inflammation [102]. In support of this notion, several studies show 
that already preschool children have evidence of remodeling, including a study where airway 
remodeling manifested in preschool children with severe wheeze, without any apparent 
relationship between airway remodeling and inflammatory cell counts in biopsies [103]. 
Furthermore, a study using an HDM-induced mouse model of early-onset airway disease, 
demonstrated that inflammation, remodeling and AHR develop in parallel rather than 
sequentially [104]. Experimental models also suggest a closer relationship between airway 
contraction, lung function and remodeling than between inflammation and remodeling, and 
show that remodeling can develop independently of inflammation [105, 106].   
Perhaps these contradictory results, indicating on one hand that airway remodeling is a 
secondary event following chronic airway inflammation, and on the other hand occurring as a 
primary event, are in fact yet another reflection of the heterogeneity of asthma and both could 
indeed hold depending on the asthma subtype.  
1.4 TREATMENT  
The mainstay of asthma management includes inhaled corticosteroids (ICSs) and short- and 
long-acting β2-adrenoceptor agonists (SABAs and LABAs).  A stepwise management 
approach with incremental dosing and additional controller medication is enforced with the 
goal to achieve symptom control and prevent exacerbations [107]. Inhaled SABAs are used 
as relievers of bronchoconstriction when required (step 1) together with ICSs as controllers to 
reduce airway inflammation (step 2). Asthma that is not well controlled by this strategy may 
benefit by supplementary therapy with inhaled LABAs or an increased dose of ICSs (step 3). 
Uncontrolled symptoms despite these efforts requires additional intervention in the form a 
forth drug such as a leukotriene receptor antagonists (LTRAs) or a further dose increase of 
inhaled corticosteroids (step 4) and as a final resort treatment with daily oral corticosteroids 
might be required (step 5).  
Conventional asthma treatments are continuously updated for new molecules as well as more 
effective and convenient delivery devices. The major drawbacks with the usage of ICS, 
LABAs, and oral corticosteroids are the risk of long-term side effects and relapse of 
symptoms after discontinuing the treatment. Furthermore, a considerable number of patients 
remain refractory despite oral corticosteroids. Even novel therapeutics that have achieved 
improvements in disease control by targeting type 2 mediators, predominantly consisting of 
monoclonal antibodies directed to IgE [108], IL-5 [109] , IL-13 [110], or IL-4[111] are only 
applicable to a subgroup of patients and do not affect the underlying dysregulated immune 
response [112].  
The only disease modulating approach for allergic asthma is allergen-specific immunotherapy 
(AIT). However, specific immunotherapy by subcutaneous injection of allergen (SCIT) is not 
very effective in controlling asthma and is associated with serious side effects, particularly in 
patients with uncontrolled and severe asthma [112, 113]. Sublingual immunotherapy (SLIT) 
with HDM extracts has shown some efficacy in asthma and seems to be well tolerated, but is 
limited to a subgroup of patients and needs to be evaluated in comparison to ICSs in long-
term studies [114]. 
 8 
Considering the limitations of available treatment strategies for asthma, including the 
considerable number of patients that remain uncontrolled, there is a need to identify 
underlying mechanisms and novel targets with the prospect of developing curative or 
preventive therapies for asthma.  
1.5 ASTHMA EXACERBATIONS 
Asthma exacerbations are defined as an exaggerated lower airway response to an 
environmental exposure [115]. When exacerbations of asthma occur, the underlying clinical 
features of asthma are accentuated with a subsequent deterioration of asthma control, often 
despite of treatment [116, 117]. Respiratory viral infections are the leading cause of asthma 
exacerbations, associated with nearly 80% of asthma exacerbation episodes [118, 119].  In 
the majority of patients with asthma, exacerbations are caused by comparably mild 
respiratory viruses, including human rhinovirus (HRV), respiratory syncytial virus (RSV), or 
by influenza virus [116]. Allergen exposure is another common cause of asthma 
exacerbations and more than 80% of children with asthma are sensitized to environmental 
allergens [117]. Common airborne allergens include house dust mites, molds, animal dander, 
weeds, trees and grass pollen [117].  
Although asthma is well-controlled in the majority of patients, a significant proportion of 
patients experience exacerbations, which are the leading cause of hospital admission in 
industrial countries among children with asthma [120]. Respiratory virus infections are major 
risk factors for hospital admissions particularly in combination with allergen exposure in 
sensitized children acting in synergy to increase the risk of hospital admission [121, 122]. 
There are currently no vaccines available for the viruses that are the leading cause of asthma 
exacerbations. Allergen-specific immunotherapy is generally not recommended for patients 
with uncontrolled asthma [112, 113]. Although, monoclonal anti-IgE antibodies 
(omalizumab) can reduce asthma exacerbations, its use is limited to the most severe cases 
because of high cost and requirement for regular injections. In conclusion, there is a need for 
improved therapeutic strategies in the prevention and management of asthma exacerbations. 
Understanding the mechanisms by which viral infections and allergen exposure exacerbate 
the pathophysiology of asthma is an important step towards improved treatment.  
1.6 THE IL-33/ST2 PATHWAY AND ASTHMA   
IL-33 is implicated as an asthma susceptibility gene through genome wide association studies 
(GWAS) and its relevance is supported by several findings in asthma patients as well as 
experimental mouse models of asthma.    
1.6.1 Genetic association of the IL-33/ST2 pathway and asthma  
Several genetic studies have linked variants in the genes for IL-33 (IL33) and its receptor ST2 
(IL1RL1) with asthma risk. This association is well established and has been replicated in 
different populations [8, 123, 124], in early childhood asthma [6], as well as in severe forms 
asthma in adults[8]. Initially, a genome wide association study (GWAS) identified single 
nucleotide polymorphisms (SNPs) in IL33 to be associated with elevated blood eosinophil 
counts, which led to a large follow up case-control study of asthma patients and control 
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subjects that indicated an association of IL33 SNPs with asthma [125]. Subsequently, a 
consortium-based GWAS of over 10, 000 asthma patients identified IL33 as one of the top 
hits for asthma. This study was later combined with a meta-analysis study, confirming the 
association between IL33 and asthma [8]. Recently, an IL33 loss-of-function mutation that 
reduces blood eosinophil counts and protects from asthma was identified in an Icelandic 
population [126].  
1.6.2 The IL-33/ST2 pathway and findings from asthma patients     
Several studies in asthma patients have highlighted the relevance of the genetic association 
between the IL-33/ST2-axis and asthma. IL-33 has been found to be increased in the 
bronchoalveolar lavage fluid, airway epithelial cells, and airway smooth muscle cells of 
patients with asthma compared with healthy controls, with a positive correlation to asthma 
severity [10, 45, 127, 128]. In addition, IL-33 has been shown to induce increased levels of 
IL-4, IL-5 and IL-13 in matured and activated cells, including mast cells, basophils and 
eosinophils, derived from allergic subjects compared to those from healthy controls [129, 
130]. There is also a link between IL-33 levels and airway remodeling, as IL-33 expression is 
increased in endobronchial biopsies derived from pediatric patients with severe therapy-
resistant asthma and correlates with reticular basement membrane thickening [11].  
1.6.3 IL-33 and experimental findings from mouse models of asthma  
Evidence for a functionally important role for IL-33/ST2 in asthma also comes from several 
experimental findings in mouse models. Intranasal administration of IL-33 has been shown to 
induce airway inflammation, promote AHR, goblet cell hyperplasia, eosinophilia as well as 
accumulation of lung IL-4, IL-5 and IL-13 [127, 131-133].     
1.6.4 Molecular aspects of IL-33  
IL-33 is a member of the IL-1 family of cytokines and was first identified as a nuclear factor 
expressed in lymph node-associated endothelial cells and was later identified as the ligand for 
the former orphan receptor ST2 [134]. Unique within the IL-1 family, IL-33 is associated 
with the promotion of type 2 immune responses.   
1.6.4.1 IL-33 production and release   
IL-33 is constitutively expressed in cell types involved in maintaining mechanical barriers 
including keratinocytes and epithelial cells in lung and gut, as well as endothelial cells, 
fibroblasts and smooth muscle cells [134-136]. Recently, the main source of IL-33 in 
response to chitin was identified to be alveolar type II cells in the distal airways [36].   
Although, IL-33 can be induced in leukocytes (including macrophages, dendritic cells, mast 
cells and monocytes) during inflammation [137-139], their relative importance as an IL-33 
source is less clear as their IL-33 expression levels are ten-fold lower relative to epithelial 
cells.    
Upon synthesis, IL-33 translocates from the cytosol to the nucleus, where it associates with 
chromatin and can regulate gene expression by several mechanisms such as the 
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downregulation of soluble ST2 and IL-6 expression, and sequestering of the nuclear factor-
κB (NF-κB) [136, 140-145]. During cell death by injury or necrosis, the stored full-length IL-
33 in the nucleus is passively released and in this context IL-33 has been classified as a 
damage-associated molecular pattern (DAMP) or an alarmin [146]. The full-length IL-33 
released under necrotic conditions is biologically active, while it is inactivated by caspase-3 
and caspase-7 during apoptosis [147]. In addition to the passive release of IL-33, a yet 
unknown mechanism for controlled IL-33 release must exist, as stimulation of different cell 
types results in release of bioactive IL-33 in the absence of cell injury and necrosis. Cardiac 
endothelial cells and fibroblasts subjected to mechanical stress release IL-33 without cell 
death [148, 149]. Exposure to HDM with proteolytic activity has been shown to trigger TLR4 
on the pulmonary epithelial cells resulting in the production of IL-33 [150]. Similarly, 
exposure of human epithelial cells to the fungus Alternaria alternata induced rapid release of 
IL-33 via ATP signaling [151]. However, the molecular mechanism by which IL-33 is 
released is enigmatic as IL-33 lacks a signal sequence that can enable classical protein 
secretion through the endoplasmic reticulum-Golgi pathway [152]. It has been suggested that 
IL-33 release can be mediated by several non-classical pathways involving different types of 
secretory vesicles [153].  
1.6.4.2 IL-33 signaling  
Once outside the cell, IL-33 acts as a classical cytokine exerting its activity by binding to a 
transmembrane heterodimer formed by its specific primary receptor ST2 (also known as 
IL1RL1, T1 or IL1R4) [134]. ST2 undergoes a conformational change after ligand binding, 
which allows for the recruitment of the co-receptor IL-1RAcP (also known as IL-1R3), 
resulting in the formation of the minimal heterodimer complex IL-33R [154]. More 
sophisticated forms of the IL-33R exist in some cell types. IL-33 signaling in mast cells can 
be synergistically amplified by the crosstalk between IL-1RAcP and the activated KIT 
receptor [155].  
Ligand binding and the subsequent formation of the IL-33R complex initiates signal 
transduction in the target cell by the MyD88-IRAK-TRAF6 signal module [156], which is 
proposed to activate at least two pathways including NF-kB and mitogen-activated protein 
MAP kinases (MAPKs) [134].  
1.6.4.3 Mechanisms modulating IL-33 activity  
Nuclear localization or retention of IL-33 is essential for limiting the inflammatory effects of 
IL-33 and thereby for maintaining immune homeostasis [157]. Following the release of IL-
33, several mechanisms could limit the bioactivity of the full-length IL-33. Soluble forms of 
ST2 (sST2) and IL-1RAcP exist, which have been proposed to function as decoy receptors to 
neutralize IL-33 [148, 149]. Moreover, inflammatory proteases derived from different cellular 
sources, including mast cells and neutrophils, are able to modulate IL-33 activity by cleaving 
the full-length protein at the N-terminal domain, thereby increasing the biological activity 
several-fold [158, 159]. Thus, the potency of IL-33 can be quickly increased at the site of 
inflammation. In contrast, disruption of the C-terminal core results in the loss of IL-33 
bioactivity, as illustrated by the potential to limit IL-33 signaling by  mast cell chymase [160, 
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161]. In addition to proteolytic cleavage, inactivation of extracellular IL-33 can be 
accomplished by oxidation of cysteine residues and the formation of disulfide bridges that 
prevent ST2 binding [162].  
1.6.4.4 ST2 expression  
The expression of ST2 is widespread, but transmembrane ST2 was initially shown to be most 
highly expressed on mast cells and to a lesser extent on TH2 cells, which led to the association 
between the IL-33/ST2 signaling pathway and the type 2 mediated diseases such as asthma 
[124, 163]. Other ST2+ cells include ILC2s, Treg cells, dendritic cells (DCs), macrophages, 
basophils and eosinophils [164].  
1.6.5 IL-33 regulation of type 2 immune responses in asthma 
IL-33 interacting with ST2 on a range of different leukocytes promotes a number of key 
inflammatory pathways of both innate and adaptive immunity that are involved in the 
initiation and propagation of allergen driven type 2 responses. This section aims to describe 
the current knowledge of IL-33 functions, from both in vivo and in vitro studies, in the 
context of allergen driven type 2 immune responses in asthma (Fig. 1).  
Following exposure to airborne allergens or respiratory viruses, IL-33 is released  from the 
pulmonary epithelium either passively, as a result of cell damage, and/or actively by 
triggering epithelial cell activation through pattern recognition receptors (PRRs), including 
Toll-like receptors (TLRs) [165]. Interestingly, exposure to HDM allergen has been shown to 
induce the release of IL-33 as a result of TLR4 triggering on the pulmonary epithelial cells 
[150]. Exposure to the fungus Alternaria in mice was reported to induce a rapid release of IL-
33 to the BALF [166]. Similarly, exposure of human epithelial cells to Alternaria induced 
rapid release of IL-33 via ATP signaling [151]. Furthermore, IL-33 can be  released as a 
result of viral infection as shown in studies in mouse ILCs infected with influenza virus 
[167].  
Released IL-33 can likely promote allergen driven responses by effects on ST2+ innate and 
adaptive immune cells that promote allergen sensitization and type 2 pathology via mainly 
generation of IL-4, IL-5 and IL-13 [22, 168]. In a naïve situation the primary tissue resident 
cells including ILC2s, mast cells, DCs, and alveolar macrophages, with a constitutive 
expression of ST2 constitute the initial targets of IL-33 [169, 170]. IL-33 is an important 
activator of ILC2s, which provide an important and early source of IL-5 and IL-13 [26]. 
Direct actions of IL-33 on mast cells include their promotion of maturation, activation, 
survival and adhesion [65, 171-173]. IL-33 has a profound effect on the phenotype of 
alveolar macrophages, driving them towards an alternatively activated (AAM) phenotype that 
contributes to innate and antigen-induced airway inflammation [127].   
Airway DCs play a crucial role as antigen presenting cells (APCs) in initiating the adaptive 
arm of type 2 responses in asthma. Dendritic cells located at the airway lumen sample and 
take up antigens and, after becoming activated, migrate to the draining lymph nodes where 
they present processed antigenic peptides on MHC class II molecules to naïve CD4+ T cells 
[174]. This mechanism defines the onset of immunological memory, which involves the 
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activation of CD4+ T cells to become IL-4 competent [15]. IL-33 has been shown to activate 
DCs by the induction of OX40 ligand (OX40L) expression that promotes the mobilization of 
DCs to local draining lymph nodes [15, 175].  
The IL-4 competent CD4+ T cells migrate to B cell zones where they differentiate into T 
follicular (TFH) helper cells or enter the circulation to mature into TH2 cells. TFH cells are able 
to induce IgE class-switching in B cells via IL-4 in the B cell follicular area, while TH2 cells 
can migrate to the airway epithelium and mediate their action through the secretion of 
cytokines such as IL-5 and IL-13 [15, 22, 176]. IL-33 can also act directly on ST2+ TH2 cells 
to promote their recruitment via an unknown mechanism [177], and to induce production of 
cytokines including IL-5 and IL-13 [130, 131, 134, 178].  
IgE+ B cells produce IgE antibodies, which in turn bind to the high-affinity IgE Fc 
immunoglobulin receptor ( FcεRI) expressed on mast cells and basophils enabling allergen-
specific activation and the rapid production of vasoactive amines and lipid mediators on 
allergen encounter [15]. IL-33 also exerts distinct effects on basophils, enhancing their IgE-
mediated degranulation, migratory capacity, and synergizes with IL-3 to promote IL-4 
production and CD11b expression [22, 179-181]. Eosinophil degranulation, adhesion and 
enhanced eosinophil survival have also been shown to be induced by IL-33 [180-182].  
Taken together, IL-33 actions on ST2+ inflammatory cells has the potential to stimulate an 
inflammatory milieu leading to enhanced type 2 responses that include both innate and 
adaptive immunity that act in concert to drive the pathology of asthma including antigen-
specific IgE production, eosinophilia, airway remodeling and AHR. Although many type of 
immune cells are ST2+, and IL-33 has been shown to modulate their activity in vitro and in 
vivo, their relative contribution to development of asthma pathophysiology remains elusive 
and needs to be put in relation to other modulatory pathways.   
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Figure 1.  IL-33 regulation of type 2 immune responses in asthma. Following exposure to airborne allergens 
or respiratory viruses, IL-33 is released from the pulmonary epithelium either passively, as a result of cell 
damage, and/or actively by triggering epithelial cell activation through pattern recognition receptors (PRRs). IL-33 
promotes the mobilization of DCs to local lymph nodes where they present processed antigenic peptides on 
MHC class II molecules to naïve CD4+ T cells. The CD4+ T cells become activated to an IL-4 competent state 
and migrate to B cell zones where they differentiate into T follicular helper (TFH) cells or enter the circulation to 
mature into TH2 cells. TFH cells are then able to induce IgE class-switching in B cells via IL-4 in the B cell follicular 
area, while TH2 cells can migrate to the airway epithelium and mediate their action through the secretion of 
cytokines such as IL-5 and IL-13. IL-33 can also activate mast cells, basophils and ILC2s to produce IL-5 and IL-
13, which mediate inflammatory and remodeling changes that predispose to asthma and asthma exacerbations. 
(Modified from [15] ). 
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1.7 IL-33 IN HEALTH AND DISEASE  
Although IL-33 has a role in contributing to the development of allergic diseases including 
asthma, it is important to recognize that the role of IL-33 can be both harmful and protective 
depending on the disease and its context [164]. Given the pleiotropic nature of IL-33 to act on 
various cells of the immune system, it is not surprising that IL-33 is involved in many 
processes, both of protective as well as harmful nature, in host defense against pathogens 
[183, 184], rheumatological diseases [185, 186], cardiovascular diseases [148, 187, 188], type 
2 diabetes [189] and inflammatory bowel disease (IBD) [190].  
1.8 MOUSE MODELS OF ASTHMA  
Mice are the most widely used species in asthma research mainly because, a wide array of 
specific reagents are available for analysis of cellular and mediator responses, and the 
availability of genetically engineered transgenic or gene-knockout mice [191].  Mouse 
models of asthma have been shown to be valuable tools in elucidating the cells and molecules 
that are responsible for pathophysiological responses in allergic airway disease [192, 193]. 
Although, asthma models can’t serve as true representations of the disease, they able to 
recapitulate important aspects of the disease including airway inflammation, AHR, and in 
chronic protocols, remodeling [192]. Since mice do not spontaneously develop these 
responses, they have to be induced. Traditional protocols use systemic sensitization with 
antigens such as ovalbumin (OVA) with an adjuvant, followed by inhalation of the antigen 
during the challenge phase to induce an acute asthma-like phenotype. More recent models 
employ the use of more physiologically relevant allergens and sensitization routes. 
Commonly used allergens in these protocols include HDM extracts, Aspergillus, and 
Alernaria alternata that are administered via repetitive inhalation over a period up to 12 
weeks [192, 194, 195]. 
The limitations of mouse models are mainly attributed to existing differences in lung anatomy 
and physiology in relation to humans. There are differences in the airway branching pattern, 
airway smooth muscle mass, as well as type and location of cells within human and mouse 
lung that can affect lung responses [196, 197]. Additionally, variability is observed within the 
mouse species, as there are strain-specific phenotype variations among common inbred 
mouse strains that exhibit considerable differences in immunological responses to the same 
allergen [198, 199]. The choice of strain depends on what aspect of asthma is being modelled. 
BALB/c mice are considered to have a more Th2-dominant immune response compared to 
C57BL/6 mice. However, most gene-manipulated mice are on the C57BL/6 background. 
Because of these differences, results obtained from studies using different mouse strains can 
be difficult to compare as they might reflect the difference in genetic background of the mice. 
Other parameters that can influence the outcome of the study include variations in 
sensitization and challenge protocols including the schedule and the route of administration 
of the allergen. In conclusion, interpolation of results from mouse to human needs to be done 
taking these limitations into considerations and ultimately, the findings in mouse models, 
need to be verified in humans.  
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2 THE PRESENT STUDY 
2.1 AIM 
This thesis investigates the role of the IL-33/ST2 pathway in asthma development, 
exacerbation and treatment using mouse models of allergic asthma.  
Specific aims 
Paper I:  To investigate the importance of IL-33/ST2 signaling for the development of 
airway hyperresponsiveness, inflammation and remodeling.   
Paper II:  To examine how IL-33/ST2-dependent mast cell responses contribute to the 
development of airway hyperresponiveness and inflammation.  
Paper III:  To elucidate the role of IL-33 in promoting exacerbation of asthma in sensitized 
subjects.  
Paper IV:  To evaluate the potential of an IL-33 vaccine for preventing the development of 
asthma.  
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2.2 MATERIALS AND METHODS 
The following sections provide a summary of the most important materials and methodology 
used in papers I-IV.  Detailed descriptions can be found in the “Materials and methods” 
section of each paper. 
2.2.1 Mice 
All animal handling and experimentation was conducted in accordance with ethical permits 
approved by the Regional Committee of Animal Experimentation Ethics (Stockholm North 
ethical committee for animal welfare; Stockholm, Sweden).  
Paper I Female BALB/c wild-type mice and IL-33 receptor-deficient (ST2-/-/Il1rl1-/-) 
mice on BALB/c background.  
Paper II Female mast cell-deficient C57BL/6-KitW-sh/W-sh mice engrafted with congenic 
bone marrow-derived mast cells (BMMCs) from female wild-type C57BL/6 
mice or IL-33 receptor-deficient (ST2-/-/Il1rl1-/-) mice on C57BL/6 background.  
Paper III Male C57BL/6 wild-type mice.   
Paper IV Female BALB/c mice.  
 
2.2.2 Study protocols 
The experimental protocols used to model allergic asthma in mice were based on exposure to 
HDM extract (papers I, II and IV) or OVA (paper III). Interventions introduced to these 
models, differences with respect to dose, routes of delivery and time intervals are outlined as 
follows.  
Paper I  Wild-type and ST2-/- mice were exposed to twelve intermittent intranasal 
instillations of HDM extract (50 μg). The outcome was assessed 48 h after the 
last HDM exposure (Fig. 2).  
 
Paper II Mast cell deficient Wsh-mice were injected intravenously with in vitro 
differentiated wild-type or ST2-/- BMMCs. Allowing 12 weeks for engraftment, 
mice were subsequently subjected to the protocol described in paper I with the 
exception that a lower HDM dose was used (25 μg) (Fig. 2).  
 
Paper III Mice were sensitized to OVA i.p. (10 μg) and subsequently challenged with 
OVA (200 μg) i.n. Administrations of IL-33 (0.2 μg) preceded each OVA-
challenge. The outcome was evaluated 24 h after the final OVA-challenge (Fig. 
3).  
Paper IV Similarly to paper I and paper II, mice were subjected to the HDM-induced 
model of allergic asthma. The dose of HDM was the same as in paper II 
(25μg). As an intervention, mice were immunized s.c. with an IL-33 vaccine 
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(100 μg), with two prophylactic doses delivered prior and one dose a week after 
the initiation of the asthma protocol (Fig. 4).  
 
 
Figure 2. The experimental protocol used to induce chronic allergic asthma in papers I, II and IV. House dust mite (HDM) or 
PBS as control were administered through intranasal instillations.  
 
 
 
 
 
Figure 3. The experimental protocol used in paper III. Mice were sham- or OVA-sensitized through intraperitoneal (i.p) injections 
and subsequently exposed to IL-33 or PBS as control through intranasal (i.n.) instillations preceding each OVA/PBS challenge. 
 
 
 
 
Figure 4. The experimental protocol used in paper IV. IL-33 vaccine or control Trx protein were administrated subcutaneously 
on day -20 and two booster injections on day -7 and 7. The HDM protocol of chronic allergic asthma was initiated on day 0.  
2.2.3 BMMC cultures   
Bone marrow derived mast cells (BMMCs) were generated in vitro by differentiating bone-
marrow cells from wild-type C57BL/6 or ST2-/- mice in the presence of IL-3 conditioned 
medium over a period of five weeks. The purity of mast cells used for lung engraftment of 
Wsh-mice exceeded 95%. 
 18 
2.2.4 IL-33 vaccine  
Rational design of the IL-33 vaccine construct (Trx-His-IL-33) is depicted in Fig. 5.  The 
vaccine fusion-protein, consisting of the coding region of the Escherichia.coli (E.coli) gene 
for thioredoxin (Trx), His6- tag and the codon-optimized IL-33 construct (IL-33), was 
expressed in E.coli. Montanide ISA720 and 1826 phosphorothioate-stabilized CpG 
oligonucleotide were used as adjuvants.  
 
 
Figure 5. Schematic structure of the recombinant IL-33 vaccine protein. Three point mutations were introduced in the mouse 
gene for IL-33 to reduce receptor binding capacity. Trx, thioredoxin; 6His, six-histidine tag.  
2.2.5 Lung mechanics  
Direct measurements of the respiratory system have been performed using the flexiVent 
system (Scireq, Montreal, PQ, Canada) and evaluated assuming the constant phase model 
(paper I-IV), which allows partitioning of lung mechanics into central and peripheral 
components.  
2.2.5.1 The constant phase model  
Respiratory input impedance (Zrs) was determined using the forced oscillation technique 
(FOT), applying pressure oscillations over a range of frequencies. Each determination of Zrs 
was fit with the constant phase model of impedance [200],  
ܼݎݏሺ݂ሻ ൌ ܴே ൅ ݅2ߨ݂ܫ ൅ ீି௜ுሺଶగ௙ሻഀ (1) 
Where RN is the Newtonian resistance closely approximating that of the conducting airways, I 
is an inertance mostly due to the mass of gas in the central airways, G represents tissue 
resistance, H characterizes tissue stiffness or elastance, i is the imaginary unit, and f is 
frequency in Hertz. G and H are linked via the parameter α through the equation:   
 
ߙ ൌ ଶగ ݐܽ݊ିଵ
ு
ீ  (2) 
Simplified, the constant phase model allows convenient partitioning of the lung mechanics 
into a central component RN (reflecting narrowing of the conducting airways) and peripheral 
components; tissue damping G (closely related to tissue resistance) and tissue elastance H.   
2.2.5.2 AHR assessment  
To assess AHR, input impedance Zrs was measured in response to incremental doses of 
acetyl-β-metacholine (Mch) delivered either intravenously (paper I, II, IV) or by aerosol 
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(paper III) and the resultant data was fitted to the constant phase model to obtain the 
parameters RN, G and H.    
2.2.6 Sample analysis 
 
Differential cell counts [I-IV] 
 
 
Differential cell counts were performed by staining 
bronchoalveolar lavage (BAL) cytospins or by flow 
cytometry on single cell suspensions from lung tissue.  
ELISA [I-IV] Enzymed linked immunosorbent assay (ELISA) was 
used to quantify proteins present in BAL fluid (BALF), 
lung tissue homogenates and serum. 
Flow cytometry [II, III] 
 
 
To quantify inflammatory cells in lung tissue, single 
cell suspensions were stained with fluorochrome-
conjugated monoclonal antibodies and analysed on an 
BD LSRFortessa cytometer. Data was analysed using 
FlowJo.  
Histology [I-IV]    
 
Sections from paraffin embedded lung tissue were 
prepared and stained to detect different structures and 
immune cells within the tissue. Hematoxylin and eosin 
staining was used to evaluate inflammatory cell 
infiltration and smooth muscle cell layer around the 
airways, periodic acid-Schiff (PAS, Sigma-Aldrich) to 
assess mucin-containing goblet cells and toluidine blue 
to quantify mast cells.  
Immunohistochemistry [I]  
 
Immunohistochemistry staining was performed on lung 
tissue to assess the presence of IL-33 in the central- and 
peripheral airways, as well as in the lung parenchyma. 
Real-time quantitative PCR [III]   Used to measure gene expression of the collagens 
Col1a1, Col3a1 and Col5a1 in lung tissue. RNA was 
extracted from lung tissue, cDNA was synthesized from 
total RNA and subsequently amplified with specific 
primer pairs. 
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2.3 RESULTS AND DISCUSSION 
IL-33 and its receptor ST2 have been implicated in several clinical and experimental studies 
to play important roles in the development of asthma. However, the effect of IL-33/ST2 
signaling on airway hyperresponsiveness and inflammation in asthma is not well established 
and is the focus of study I-IV included in this thesis. In study I, we described how ST2 
deficiency affects airway hyperresponsiveness, inflammation and remodeling, all cardinal 
features of allergic asthma. We then continued by investigating how mast cells contribute to 
these processes in study II, where ST2 deficiency was limited to mast cells. Study III, 
explored the potential of IL-33 to exacerbate allergic asthma in sensitized subjects. The 
effects of IL-33 blocking during the developmental stages of asthma by an IL-33 vaccine was 
evaluated in study IV. 
2.3.1 The interleukin-33 receptor ST2 is important for the development of 
peripheral airway hyperresponsiveness and inflammation in a house 
dust mite mouse model of asthma (paper I) 
To investigate the role of IL-33/ST2 signaling in promoting asthma development we 
employed a mouse model of allergic asthma that we established, evaluated and optimized 
extensively prior to this study. The model is based on intermittent intranasal exposures to 
HDM (Fig. 2) and has been validated to induce robust chronic inflammatory responses 
including AHR, airway inflammation, remodeling and antigen-specific IgE production. We 
chose to evaluate the outcome 48 h after the final HDM exposure, as this was the time point 
that gave the strongest response for the lung parameters RN, G and H in a pilot study where 
airway responses were evaluated on day 1, 2 and 7 after the last HDM exposure. In this study, 
ST2-/- mice and wild-type BALB/c mice were exposed to HDM extract or PBS as control 
through intranasal instillations.  
Asthma has been characterized as an inflammatory condition affecting first the larger airways 
and eventually the smaller airways. However, it has also been suggested that the peripheral 
airway involvement might define a distinct and more severe phenotype of asthma [201]. 
Since the relative involvement of the central airways versus the peripheral airways has 
important implications for asthma management [201-203], we thought it is necessary to 
differentiate between these two compartments when studying pathways involved in asthma 
development. For this reason, we used the constant-phase model to fit respiratory input 
impedance, which makes it possible to partition the lung parameters into a central component 
RN (reflecting narrowing of the conductive airways), and a peripheral component defined by 
G and H (reflecting constriction of small airways and alterations in intrinsic lung tissue 
properties) [204]. We observed that wild-type mice developed a pronounced HDM-induced 
AHR in both central airways (RN) and peripheral lung (G and H) relative to the baseline 
produced by the PBS control mice (Fig. 6). ST2-/- mice developed a similar HDM-induced 
response in RN as wild-type mice, indicating that development of AHR in the conducting 
airways was independent of the IL-33/ST2 pathway. Interestingly, AHR development in the 
peripheral lung was significantly suppressed in ST2-/- mice as shown by a marked reduction 
in both G and H. We thereby show distinct effects of HDM-induced ST2 signaling in these 
two compartments, which suggests that this pathway does not significantly affect the 
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conductive airways, but instead is important for the development of peripheral changes that 
contribute to AHR. This distinct effect could be due to distribution of inflammatory cells that 
express the ST2 receptor and/or that the ability of HDM to induce IL-33 release is greater in 
the periphery, thereby having a greater impact on responses in this compartment. Other 
studies have previously linked activation of the IL-33/ST2-pathway with the induction of 
AHR. Using OVA and ragweed as antigens, AHR was shown to be reduced by blocking 
antibodies as evaluated by whole-body plethysmograph [35, 205]. Furthermore, reduction in 
AHR was observed in studies using invasive measurements of lung function in IL-33- 
deficient mice with ovalbumin as antigen and in neonatal ST2-deficient mice following HDM 
exposure [11, 206]. However, these studies report only AHR as assessed by overall lung 
resistance, losing the important information regarding what compartment contributes most 
significantly to this effect.   
Figure 6. ST2-/- mice show attenuated airway hyperresponsiveness to metacholine in the peripheral lung, as assessed by G and 
H, compared to wild-type mice. (a) Newtonian resistance RN of the conducting airways, (b) tissue damping G, and (c) tissue 
elastance H.   
We also observed that ST2 deficiency suppressed pulmonary inflammation and remodeling. 
Cellular inflammation was assessed in BALF and sections of lung tissue. The number of 
inflammatory cells in the BALF of ST2-/- mice was considerably lower than in their wild-type 
counterpart (Fig. 7). The most abundant cells in this model were eosinophils and 
macrophages.   
 
Figure 7. ST2-/- mice have decreased levels of inflammatory cells in bronchoalveolar lavage fluid (BALF) after house dust 
mite (HDM) exposure compared to wild-type mice. Cellular inflammation, as reflected in the numbers of total and 
differentiatial cell count of leukocytes in BALF from wild-type and ST2-/- mice treated with HDM extract or PBS. Mean values 
± SEM are depicted (n = 7–8 for eachgroup). *P < 0.05, **P < 0.01, ***P < 0.001. 
Since we mainly observed effect of ST2-deficiency on peripheral AHR, we wanted to 
investigate inflammation and remodeling in the peripheral airways in relation to the central 
airways. We could not observe a significant change in the cellular infiltration around the 
central airways in lung sections when comparing HDM exposed wild-type and ST2-/- mice. 
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However, we did find a lower degree of inflammation in the peripheral airways of the HDM 
exposed ST2-/- mice (Fig. 8a). This effect was also present when evaluating remodeling, 
where the HDM-induced goblet hyperplasia seen in the wild-type mice was significantly 
reduced in the peripheral airways of the ST2-/- mice (Fig. 8b).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Semiquantitative scoring of the severity of (a) inflammatory cell infiltration and (b) mucus in the peripheral airways. 
ST2-/- mice exposed to HDM have diminished inflammation and mucus in the peripheral airways compared to wild-type mice.    
ST2 deficiency also reduced the levels of HDM-specific serum IgE. Although, mast cell 
numbers were not affected, HDM exposure of ST2-/- led to a decrease in the level of the mast 
cell protease mMCP-1 in BALF. The levels of the HDM-induced inflammatory cytokines 
including the Th2 cytokines IL-5 and IL-13, Th1 cytokine IL-1β and the epithelial-derrived 
cytokines IL-33 and GM-CSF were also attenuated in lung homogenates of ST2-/- mice. The 
decrease of IL-5 and IL-13 may explain the reduced eosinophilia, and goblet cell hyperplasia 
and AHR, respectively, that is observed in the ST2-/- mice.  
When investigating the distribution of IL-33 following HDM exposure in the lung with 
immunohistochemistry, we observed that the epithelial cell layer in both the central and 
peripheral airways showed a decrease, whereas the parenchyma showed a marked increase in 
IL-33. The inflammatory effects in the peripheral lung airways and possibly the subsequent 
AHR response may be explained by a high induction of IL-33 by alveolar epithelial cells, 
alveolar machropages and type II alveolar pnemocytes and the presence of IL-33 responsive 
cells in the peripheral lung compartment [136, 207].  
In conclusion, these results suggest a possible asthma phenotype that involves the IL-33/ST2 
pathway and is important for the development of airway inflammation and subsequently 
AHR in the peripheral airways. A feasible explanation for the effect on the peripheral lung 
function is a combined IL-33 driven increase in peripheral inflammation and mucus 
production that causes airway closure and thereby increases both parameters G and H.  
  
a b
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2.3.2 Mast cell dependent IL-33/ST2 signalling is protective against the 
development of airway hyperresponsiveness in a house dust mite 
mouse model of asthma (paper II) 
In paper I, we showed that ST2 is important for the development of peripheral airway 
hyperresponsiveness and lung inflammation in a HDM mouse model of allergic asthma. 
Based on these findings, we wanted to investigate the role of mast cells in this setting and 
hypothesized that IL-33/ST2-dependent mast cell responses would contribute to the 
development of AHR and inflammation.  
In order to test this hypothesis, mast cell deficient C57BL/6-KitW-sh/W-sh mice were engrafted 
with either wild-type (Wsh+MC-WT) or ST2 deficient (Wsh+MC-ST2KO) bone marrow 
derived mast cells (BMMCs). Allowing 12 weeks for lung engraftment, the mice were 
subsequently subjected to a HDM protocol (Fig. 2). Mast cell engraftment of the lung 
compartment was confirmed and was similar in all the groups investigated (Fig. 9). The 
engraftment was limited to the peripheral lung, predominantly to the alveolar parenchyma, 
while mast cells were absent around the central airways. This distribution of mast cells in the 
engrafted Wsh mice is in accordance with previous observations and contrasts to the wild-
type situation, in which mast cells can be predominantly found around the central airways 
[208]. Mast cell localization in humans is more similar to the one found in Wsh mice after 
mast cell engraftment than to the one in wild-type mice. Therefore, in that aspect, it could be 
argued that the reconstituted Wsh-mouse is a more relevant model of asthma.  
 
Figure 9. Mast cell deficient C57BL/6-KitW-sh/W-sh mice engrafted with WT or ST2KO BMMCs. Mast cell engraftment of lung tissue 
evaluated at day 44. Each point represents the mean of mast cell counting from 3-6 lung sections. (Results are expressed as 
mean of n=8-11 mice in each group.) 
Unexpectedly, we discovered an exacerbated development of peripheral AHR in Wsh mice 
engrafted with ST2 deficient mast cells (Wsh+MC-ST2KO) rather than mast cells with a 
functional ST2 receptor (Wsh+MC-WT) (Fig. 10). This interesting finding suggests that ST2-
dependent mast cell responses can play a protective, rather than causative role in the 
development of AHR. A protective role for mast cells on airway responses were reported in a 
study where mast cell deficient mice exhibited exacerbated airway eosinophila in comparison 
with wild-type mice after inhalation of low-dose papain or low-dose IL-33 [209]. 
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Figure 10. Mast cell dependent IL-33/ST2 signaling protects against the development of airway hyperresponsiveness. Airway 
hyperresponsiveness (AHR) in response to intravenously delivered methacholine (Mch) was assessed in intubated and 
ventilated Wsh mice (flexiVent ventilator) engrafted with either wild-type (Wsh+MC-WT) or ST2 deficient (Wsh+MC-ST2KO) 
mast cells and exposed to HDM extract or PBS. (a) Newtonian resistance (RN) of the central airways, (b) tissue damping (G) and 
(c) tissue elastance (H). **p<0.01, ***p<0.001 (ANOVA, Bonferroni). Results are expressed as mean ±SEM of n=8-11 mice in 
each group.  
Next, we investigated how ST2-deficiency in mast cells affected the inflammatory 
parameters. We did not observe any significant reduction in cellular infiltration in the BALF 
and lung accompanying the diminished peripheral AHR in HDM exposed Wsh-mice 
engrafted with mast cells expressing the ST2 receptor (Wsh+MC-WT) compared with those 
deficient in ST2 (Wsh+MC-ST2KO), which suggests a mechanism independent of the 
accumulation of inflammatory cells in these compartments. However, the protective effect on 
AHR was associated with higher levels of PGE2 in BALF (Fig. 11). A protective role for 
PGE2 has been reported previously in asthma patients  and inhalation of PGE2 prevents early 
and late airway responses after allergen challenge, which can be explained in terms of 
inhibition of the airway smooth muscle constriction and suppression of mast cell mediators 
[210].  
The protective response on AHR mediated by PGE2 could thus in this study be explained 
both in terms of inhibition of the airway smooth muscle constriction and suppression of mast 
cell mediators or by a yet not identified mechanism. The question remains as to what 
mechanism mediates the elevated PGE2 levels in our model. One possibility is that IL-33 
induces PGE2 synthesis and release directly from mast cells or through an intermediate mast 
cell mediator acting on a PGE2 releasing target cell. Elevated PGE2 levels could in turn have a 
direct relaxing effect on the airway smooth muscle and/or an inhibitory effect on mast cell 
activity through the PGE2-mast cell axis subsequently diminishing AHR [211, 212].  
 
Figure 11. PGE2 levels were determined in BALF. *p<0.05, **p<0.01 
and ***p<0.001 (ANOVA, Bonferroni). Results are expressed as 
mean ±SEM of n=6-11 mice in each group.     
In summary, we have revealed a protective role 
for IL-33/ST2-dependent mast cell responses in 
the development of AHR in the peripheral lung 
that seems to be independent of cellular 
inflammation yet is associated with elevated PGE2 
levels. More studies are needed to understand the 
mechanisms underlying the observed effects. 
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2.3.3 Interleukin 33 exacerbates antigen driven airway hyperresponsiveness, 
inflammation and remodeling in a mouse model of asthma (paper III) 
IL-33 has been identified as a key player in the initiation of asthma pathogenesis. 
Furthermore, inappropriate and excessive secretion of IL-33 by environmental triggers could 
exacerbate an unresolved airway inflammation. The most common triggers of asthma 
exacerbations are respiratory virus infections which are major risk factors for hospital 
admissions, particularly in combination with allergen exposure in sensitized children acting 
in synergy to increase the risk of hospital admission [121, 122]. Respiratory viruses and 
allergens have both been reported to induce IL-33 release from the airway epithelium and 
dsRNA challenges were reported to produce exacerbation effects in mice with established 
HDM-induced asthma [213]. With regards to these observations, we hypothesized that IL-33 
together with allergen exposure would exacerbate asthma responses in sensitized subjects.  
To test our hypothesis, we used a mouse model of asthma in which mice were sensitized to 
ovalbumin (OVA) (without adjuvant) (Fig. 3). These sensitized mice were subsequently 
exposed to IL-33 through intranasal instillation before each OVA-challenge. We observed 
that IL-33 exacerbated many features characteristic of asthma including antigen-induced 
airway inflammation, AHR and remodeling.  
IL-33 administration to OVA-sensitized and challenged mice (OVA+IL-33 group) 
aggravated antigen-induced AHR in the conductive airways as well as in the peripheral lung, 
as evaluated by increased RN, and G and H, respectively in response to increasing doses of 
methacholine (Fig. 12).  
 
Figure 12. IL-33 potentiates antigen induced airway hyperresponsiveness. Airway hyperresponsiveness (AHR) in response to 
inhaled methacholine was measured in sham- or OVA-sensitized C57BL/6 mice that received intranasal instillations of IL-33 or 
PBS. Maximal responses to increasing doses of methacholine are shown for Newtonian resistance (Rn), tissue damping (G) and 
tissue elastance (H) * p < 0.05 (ANOVA, Bonferroni). Results are pooled data from four independent experiments (mean ±SEM 
of n=9-10 mice for each group).   
Exposure to IL-33 alone in mice that were not sensitized and challenged with OVA (IL-33 
group), also induced marked increases in RN, G and H, that were comparable to those in mice 
that were sensitized and challenged with OVA but not exposed to IL-33 (OVA group). 
Intranasal administration of IL-33 has previously been shown to induce AHR in BALB/c 
mice. AHR in response to intranasal OVA instillations to sensitized mice has similarly been 
observed in another study [214].  
We then investigated whether the combined action of IL-33 and OVA exposure in sensitized 
mice would also enhance airway inflammation. Indeed, the total number of inflammatory 
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cells and in particular eosinophils in BALF (Fig. 13a), as well as lung tissue inflammation in 
large airways as well as peripheral lung tissue (Fig. 13b), were severely elevated in the 
OVA+IL-33 group compared to all the other groups.  
 
 
  
 
.  
 
 
 
Figure 13. IL-33 potentiates antigen induced inflammation in BALF and the lung tissue. (a) Differential cell counts in BALF. (b) 
Representative images of haematoxylin and eosin staining of lung tissue. * p < 0.05, **p<0.01, ***p<0.001 (ANOVA, Bonferroni). 
Results are pooled data from four independent experiments (mean ±SEM of n=9-10 mice for each group).  
Intranasal instillations of IL-33 have previously been shown to induce an increase of 
eosinophils in murine airways [132]. 
We could also demonstrate how IL-33 together with OVA-sensitization and challenge 
affected airway remodeling by measuring the expression levels of three collagen genes;  
Col1a1, Col3a1 and Col5a1 that have been shown to be involved in reticular basement 
membrane fibrosis in asthma [179], and by assessing the smooth muscle thickness around the 
central airways. The expression levels of Col1a1 and Col3a1 were elevated in the OVA+IL-
33 group (Fig. 14a), while IL-33 or OVA alone did not induce expression of the measured 
collagen genes. Similarly, increase in smooth muscle thickness around the central airways 
was only increased in the OVA+IL-33 group (Fig. 14b).     
 
 
 
 
 
Figure 14. IL-33 together with OVA leads to airway remodeling. (a) Scoring of the ASM cell layer around the central airways. 
The thickness of the ASM cell layer was assessed and a relative score was assigned to each sample, where 0=normal, 
1=thickened and 2=substantially thickened ASM cell layer. ASM=airway smooth muscle. *p<0.05 (Chi-square test for trend). 
Results are pooled data from four independent experiments (mean ±SEM of n=9-10 mice for each group). (b) Relative 
quantitation (RQ) of mRNA levels of Col1a1, Col3a1 and Col5a1 were assessed in lung specimens. *p<0.05, **p<0.01 (ANOVA, 
Bonferroni). Results are pooled data from four independent experiments (mean ± SEM of n=3-4 mice in each group).  
a b
a b
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It has previously been shown that collagen levels in the lung are increased following two 
weeks of intranasal IL-33 instillations in BALB/c mice [11]. This was not observed in our 
study in which C57BL/6 mice were exposed to IL-33 for a shorter duration. However, an 
increase in collagen expression could be observed when IL-33 was combined with OVA.  
Increased collagen deposition and smooth muscle thickening around the airways reduces the 
elasticity of the airways and as such, our data suggest that the combined effects of OVA and 
IL-33 exposure on remodeling of the airways can lead to airflow obstructions.  
Taken together we could see that IL-33 exacerbates common features of asthma including 
AHR, airway inflammation and remodeling. We then wanted to investigate how these 
observations related to several of the type 2 associated inflammatory responses including 
antigen-specific IgE production, type 2 cytokine release, mast cell recruitment and activation,  
and the induction of IL-33 responsive cells including ILC2s.  
We could see a striking increase in antigen-specific IgE production induced by IL-33 
exposure in OVA sensitized and challenged mice (OVA+IL-33 group) (Fig. 15a), as well as 
marked increase in the levels of type 2 cytokines IL-4, IL-5 and IL-13, compared to the other 
groups (Fig. 15b).    
 
Figure 15. IL-33 exposure enhances antigen induced OVA specific IgE and increases lung cytokine levels in OVA-sensitized 
mice. (a) Serum specimens were analyzed to determine the levels of anti-OVA IgE Abs. n.d.= not detectable. **p<0.01 (ANOVA, 
Bonferroni). Data are representative of two independent experiments with similar results (mean ±SEM of n=5-6 mice in each 
group) (b) Lung homogenates were analyzed for cytokine levels. *p<0.05, **p<0.01, ***p<0.001 (ANOVA, Bonferroni). Results 
are pooled data of four independent experiments (mean ±SEM of n=4-6 mice in each group). 
It has previously been reported that intraperitoneal IL-33 administration to naïve mice 
amplified IgE synthesis, independent of antigen, via IL-4 acting on B-cells and that the main 
source of this cytokine are mast cells and eosinophils [215]. IL-33 enhanced antigen-
presentation and activation of naïve CD4+ T cells, and subsequent induction of IgE class-
switching in B cells via IL-4, could also explain the enhanced antigen-specific IgE levels. 
The elevated IL-5 and IL-13 levels could account for the observed IL-33 enhanced airway 
eosinophilia, and AHR and remodeling, respectively.   
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When evaluating mast cell density in the lungs, we could not see any significant differences 
in mast cell expansion in any of the experimental groups. We then hypothesized that the 
exacerbated airway responses by IL-33 could be explained by an enhancement of mast cell 
mediator release as opposed to elevated mast cell numbers. Indeed, we could observe 
elevated levels of the mast cell mediator mMCP-1, which suggests enhanced mast cell 
activity. This could be due to increased levels of antigen-specific IgE leading to more 
frequent mast cell degranulation upon antigen encounter or that IL-33 can act directly on 
sensitized mast cells to increase the storage of mast cell mediators leading to more potent 
degranulation after IgE cross-linking by antigen. Thus, IL-33 could enhance mast cell 
responses via an indirect amplification of antigen-specific IgE driven by elevated IL-4 levels 
as well as directly potentiating mast cell responses by increasing the storage of mast cell 
mediators.   
The increases in type 2 cytokines could be explained by enhanced activity of TH2 cells, either 
by a direct action of IL-33 on these ST2+ cells or indirectly through increased activation and 
differentiation of CD4+ naïve T cells to effector TH2 cells by IL-33 activated DCs. Another 
important source of type 2 cytokines, mainly IL-5 and IL-13, are the highly IL-33 responsive 
ILC2s. ILC2s are innate tissue resident cells that are considered to constitute a potent and 
earlier source of IL-5 and IL-13. Interestingly, we observed a prominent increase in 
pulmonary ILC2s, identified as SSClowFSClowCD45+Lin-ICOS+KLRG1+Sca-1+CD25+ ST2+ 
cells,  when OVA-sensitized mice were exposed to IL-33 (Fig. 16), suggesting that ILC2s 
could be involved in the IL-33 mediated exacerbations of allergen-induced asthmatic 
responses presented herein.   
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Figure 16. IL-33 enhances the accumulation of pulmonary ILC2s in OVA-sensitized mice. Flow cytometric analysis of lung cells. 
(a) ILC2s were identified as SSClowFSClowCD45+Lin-ICOS+KLRG1+Sca-1+CD25+ST2+ cells. Gates were set based on FMO 
controls, FMO ctrl= overlay of the two FMO controls for each respective plot. The representative FMO plots and plots showing 
the representative SSClowFSClowCD45+ gating belong to the OVA+IL-33 group. (b) Frequency and numbers of pulmonary ILC2s. 
*p<0.05, **p<0.01, ***p<0.001 (ANOVA, Bonferroni). Results are pooled data of four independent experiments (mean ±SEM of 
n=8 mice in each group). 
In conclusion, this study provides evidence that IL-33 exacerbates antigen-driven features of 
allergic asthma and we propose that mast cells and ILC2s have a central role in driving these 
processes. It remains elusive whether the observations we report herein can be coupled to the 
exacerbation of asthma symptoms observed in sensitized individuals. Exacerbations of 
allergic asthma could be explained by an inappropriate and excessive release of IL-33 caused 
by epithelial triggers such as viral infection. Collectively, our data suggests that IL-33 
constitutes a potential target for the management and prevention of asthma exacerbations.  
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2.3.4 Vaccination against IL-33 inhibits airway hyperresponsiveness and 
inflammation in a house dust mite model of asthma (paper IV) 
In paper IV, we evaluated a vaccination strategy that targets IL-33. The rationale behind the 
design of this vaccine was analogous with vaccination strategies for preventing infectious 
disease; to induce immunological memory responses to an antigen. However, vaccination 
against endogenous antigens such as IL-33 poses a problem with regard to self-tolerance. In 
order to overcome this, the self-antigen must be modified by insertion of dominant T cell 
epitopes or linking  it to a non-self-antigen [216]. Here, the recombinant IL-33 was coupled 
to a small redox protein called thioredoxin derived from E.coli creating a recombinant fusion 
protein (Fig. 5). Furthermore, three point mutations were introduced to the recombinant IL-33 
protein with the purpose to reduce receptor binding capacity, while retaining most of its B 
cell epitopes. The modified IL-33 vaccine protein was used together with the adjuvants 
Montanide ISA 720 and phosphorothioate stabilized CpG oligonucleotide 1826, which have 
previously been shown to be effective in vaccination against endogenous antigens [217-220].  
The efficacy of this vaccine was evaluated in our mouse model of HDM-induced asthma 
using a prophylactic strategy where female BALB/c mice were immunized subcutaneously 
with the IL-33 vaccine or the carrier protein (Trx) with the adjuvants as control (Fig. 4).  
First, we tested whether the IL-33 vaccine was able to elicit a humoral response with the 
production of blocking IgG-antibodies against IL-33. The presence of anti-IL-33 IgG was 
determined using ELISA and revealed that high titers of anti-IL-33 antibodies were obtained 
on days 20 and 44 in vaccinated mice (Fig. 17). These observations suggested that the 
recombinant IL-33 vaccine was immunogenic. We then wanted to investigate whether the 
induction of IL-33 blocking antibodies could ameliorate the effect of HDM-induced airway 
responses.  
 
Figure 17. IL-33 vaccine elicits anti-IL33 specific antibodies. Serum samples of anti-IL-33 IgG on days 20 and days 44. All 
values shown are means ± s.e.m (n = 10 mice in each group on day 20; n = 9 mice in HDM+Vaccine group, n = 10 in 
PBS+Vaccine group and n = 10 in Trx+HDM group on day 44, ** P < 0.01, *** P < 0.001 in comparison to the Trx + HDM group. 
Vacc: IL-33 vaccine, Trx: thioredoxin, HDM: housedust mite, N.D.: not detected. 
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By evaluating AHR in response to increasing doses of MCh we observed that the HDM-
induced (HDM+Trx) resistance in the conducting airways RN was attenuated by 
approximately 50% and tissue resistance G was completely abolished by the IL-33-vaccine 
(HDM+vaccine), indicating an  IL-33 dependent effect on both conductive and distal airways 
in this model (Fig. 18). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Vaccination against IL-33 diminishes house dust mite-induced airway hyperresponsiveness to methacholine. The 
resistance of the central airways (Rn), pulmonary tissue damping (G) and tissue elastance (H) to methacholine (Mch) were 
assessed employing a flexiVent. All values shown are mean ± s.e.m. (n = 8 mice in HDM+Vaccine group, n = 9 mice in 
Trx+HDM group and n = 6 mice in PBS+Vaccine group, missing samples due to unsuccessful or uncompleted intravenous 
injection in the animals) *P < 0.05, ** P < 0.01 in comparison to the Trx+HDM group. Vacc: IL-33 vaccine, Trx:thioredoxin, 
HDM: house dust mite. 
When we investigated the effect of IL-33 vaccination on inflammation we discovered that the 
HDM evoked inflammation (HDM+Trx) was suppressed by the IL-33 vaccine 
(HDM+vaccine) as eosinophilia was considerably diminished in BALF (Fig. 19a), and  lung 
tissue inflammation was reduced (Fig. 19b). This finding is in agreement with previous 
studies reporting that blocking IL-33 with mAbs attenuated OVA-induced eosinophil 
infiltration [221, 222]. We also observed that the IL-33 vaccine attenuated the HDM-induced 
levels of the inflammatory cytokines including IL-25, IL-33, TSLP, and IL17A, but did not 
have an effect on the levels of IL-5 and IL-13. A possible explanation for the absence of an 
effect on IL-5 and IL-13 is that we could have missed the window where these cytokines 
peak, which has been reported to occur four hours after the final HDM exposure [223].  
 
 
 
 
 
 
 
Figure 19. Vaccination of mice against IL-33 attenuates the increase in the number of inflammatory cells present in 
bronchoalveolar lavage fluids and pulmonary tissue inflammation. (a)Total and differential cell counts were performed on 
cytospin preparations of the BALF. (b) Semi-quantitative scoring of hematoxylin and eosin (H&E) staining. All values shown 
are mean ± s.e.m. (n = 9 mice in HDM+Vaccine group, n = 10 mice in PBS+Vaccine group and n = 10 mice in Trx+HDM 
group, missing sample due to failed collection of BALF from the animal). * P < 0.05 in comparison to the Trx+HDM group. 
Vacc: IL-33 vaccine, Trx: thioredoxin, HDM: house dust mite, TC: total cell count, neu: neutrophils, eos: eosinophils, 
mac:macrophages, lym: lymphocytes. 
a b
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In summary, we have shown that a novel IL-33 vaccine elicits high titers of antibodies to IL-
33 that are sustained and significantly inhibit HDM-induced AHR, airway inflammation and 
production of pro-inflammatory cytokines. These observations lend further support to the 
proposal that IL-33 plays a key role in the initial pathogenesis of asthma [28]. Thus, the IL-33 
vaccine can serve as a tool to elucidate the role of IL-33 in allergen-induced asthma responses 
and as our results suggest could be further evaluated for therapeutic purposes. Exacerbations 
of asthma might in part be driven by IL-33, as suggested by the results in study III, thus 
blocking IL-33 could also prove to be an effective therapeutic tool for management and 
prevention of asthma exacerbations in addition to treatment of asthma phenotypes where IL-
33 is implicated [224]. 
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2.4 CONCLUSIONS 
 
The main conclusions from this thesis are: 
Paper I: The IL-33/ST2 pathway contributes to the development of several characteristic 
features of asthma, including AHR, inflammation and remodeling. Importantly, this study 
shows that the ST2-dependent contribution to AHR mainly resides within the peripheral lung 
compartment. We suggest that this effect is driven by peripheral inflammation and airway 
remodeling that causes airway closure. Thus, the IL-33/ST2 pathway may constitute an 
important target in the treatment of small airway disease.   
Paper II: Mast cell responses can have a protective role in the development of AHR by 
constraining the deleterious IL-33/ST2 mediated responses. This study also supports the 
notion that AHR can be an event occurring independent of airway inflammation. We suggest 
that ST2 dependent mast cell responses attenuate AHR at least in part through the induction 
of bronchoprotective PGE2.      
Paper III: IL-33 exacerbates allergen-induced airway responses including AHR, 
inflammation and remodeling. Particularly, IL-33 exposure following antigen sensitization 
enhances AHR in the conductive airways as well as in the peripheral lung compartment, 
boosts antigen-specific IgE production, and leads to the expansion of ST2+ ILC2s. We 
conclude that since exacerbations of allergic asthma could be explained by an inappropriate 
and excessive release of IL-33 caused by epithelial triggers such as viral infections, IL-33 
constitutes a potential target for the management and prevention of asthma exacerbations.   
Paper IV: The development of asthma features including AHR, airway inflammation and 
remodeling can be at least in part prevented by a vaccination strategy using a recombinant IL-
33 protein that induces the production of IL-33 blocking IgG antibodies. These observations 
further support the key role of IL-33 in the establishment of asthma. Furthermore, since IL-33 
likely contributes to asthma exacerbation, this vaccine strategy represents a potential 
therapeutic tool for the prevention and treatment of asthma exacerbations.  
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2.5 FINAL REFLECTIONS AND FUTURE PERSPECTIVES  
This thesis investigated the role of the IL-33/ST2-pathway in mouse models of allergen-
induced asthma. The knowledge gained from the work in this thesis provides further evidence 
and new insights into the importance of this pathway in asthma. In this section, I present 
some of my reflections and speculations regarding the research field related to the IL-33/ST2-
pathway in asthma, which would be interesting to address in the future.      
The origins of asthma remains enigmatic but is considered to be caused by environmental 
triggers in genetically predisposed individuals. Only a few genes have consistently been 
associated to asthma. Two of the most replicated candidate genes for asthma from large 
genome-wide association studies (GWAS) include the genes for IL-33 (IL33) and ST2 
(IL1RL1). Single nucleotide polymorphisms (SNPs) in and flanking these genes are thus 
associated with increased susceptibility to asthma. It is interesting to consider how these 
genetic variants translate into consequences for protein expression, structure, and ultimately 
the activity of the IL-33/ST2-pathway. At present, this knowledge is very limited. However, 
SNPs can in general be translated into functional alterations by two main mechanisms; 
through changes in the level of expression or through amino acid substitutions that can alter 
protein structure and function. Most of the IL33 associated SNPs are located 5’ of the gene or 
in the first intron, while some IL1RL1 associated SNPs are also located in exons [225]. These 
observations suggest that IL-33 activity could mainly be affected by increased expression, 
while ST2 could also be associated with structural and functional alterations of the protein. 
Interestingly, a recent study identified a loss-of-function sequence variant in the gene for IL33 
that resulted in reduced expression and a truncated form of IL-33 that lacked cytokine activity 
due to an inability to bind to the ST2 receptor, and as a consequence was associated with 
attenuated  inflammatory responses leading to reduced eosinophil counts [126]. It is tempting 
to speculate that other genetic variants of IL33 and IL1RL1 exist that could result in structural 
alterations that instead potentiates their activity. It would be of great interest to identify the 
structural and functional consequences for these gene variants.  
In paper III, we showed that exposure of sensitized mice to IL-33 exacerbated allergen-
induced AHR, inflammation and remodeling. This approach can be seen as a way to mimic 
asthma exacerbations as a consequence of insults such as virus infections that lead to IL-33 
release or it could also be seen as a way to simulate an excessive IL-33 release caused by a 
genetic variant. However, it does not address the effects of a functionally different IL-33. 
Under the assumption that genetic variants of IL-33 leading to structural alterations could be 
identified and expressed as recombinant proteins, it would be very interesting to investigate 
their effects in our model. Similarly to the more biologically active splice variants of IL-33 
created after cleavage by inflammatory proteases from mast cells and neutrophils [158, 159], 
genetic variants of IL-33 resulting in a truncated or alternatively folded protein could lead to 
enhanced biological activity. There are several ways through which enhanced biological 
activity could be conferred; higher affinity of IL-33 to the ST2 receptor, enhanced stability of 
IL-33, unresponsiveness to negative regulation such as sST2 binding and proteolytic 
inactivation of IL-33, impaired retention capability in the cell nucleus resulting in aberrant 
release, and altered ability to recruit accessory proteins to the IL-33R complex after IL-33 
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binding. The latter is especially compelling, since it could lead to amplified signaling 
transduction, such as the one that exist in mast cells where KIT is recruited to the heterodimer 
that is formed by ST2 and its accessory receptor IL-1RAcP after IL-33 binding, which leads 
to a synergistic amplification of IL-33 signaling [155]. In addition to amplified signaling, 
such a possibility also implies that different IL-33 variants could selectively activate different 
cells, depending on their expression of co-receptors and accessory proteins. The expression of 
KIT in non-neoplastic cells is restricted to hematopoietic stem cells, progenitor cells, mast 
cells and ILC2s. Different IL-33R complexes could be important in other cell types. 
Extending on this thought; different IL-33 variants could induce different inflammatory 
profiles by the activation of different immune cells, and perhaps these profiles could be 
translated into asthma subtypes i.e. different IL-33 variants may be of distinctive importance 
depending on asthma subtype.  
Additionally, the presence of IL-33 protein variants could have important implications for 
therapeutic approaches targeting IL-33, as IL-33 inhibitors need to target all biologically 
active IL-33 variants. Similarly, this needs to be taken into consideration when developing 
anti-IL-33 antibodies used in various assays for measuring IL-33 levels in patients. In study 
IV, we evaluated the potential of an IL-33 vaccine for preventing the development of asthma 
in a mouse model. This strategy proved effective in our model, in which IL-33 specific IgG 
antibodies were induced that attenuated AHR and inflammation. Vaccination against IL-33 
opens an interesting possibility in the context of this discussion. Perhaps the IL-33 antigen 
used for vaccination could be modified to selectively induce blocking antibodies to more 
effectively target specific IL-33 variants.   
In addition to the functional consequences of IL33 variants, little is known about how IL-33 
release is regulated. It is relatively well established that insults resulting in necrotic cell death 
leads to a passive release of IL-33 from the nucleus [146]. Less is known about the triggers 
that result in active IL-33 release, although it is evidently possible as illustrated by studies 
that show IL-33 release without any apparent cell death [150, 151]. What further adds to the 
enigma is how IL-33 secretion can occur in the first place as IL-33 is translated without a 
signal sequence for secretion via the classical-pathway (endoplasmic reticulum/golgi 
pathway). It is possible that IL-33 release can be mediated by different non-classical 
pathways involving other types of secretory vesicles such as exosomes [153].  
It is tempting to speculate that polymorphism in genes for effector molecules involved in 
regulating the release and activity of IL-33 are of equal importance. I believe that insights 
into the mechanisms of IL-33 release regulation during different developmental stages in 
response to environmental factors are of key value in understanding the pathogenesis of 
asthma. In this scenario, events upstream of IL-33 release are of critical value as these could 
constitute potential targets to prevent aberrant IL-33 release from occurring in the first place. 
Furthermore, they could provide more selective targeting of IL-33 under the assumption of a 
more specialized regulation of IL-33 release by specific triggers. This selective targeting 
would be particularly desirable considering the protective role of IL-33 in several diseases 
including cardiovascular diseases [148, 187, 188].  
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An interesting aspect is the interaction of environmental stimuli such as allergens and viruses 
with epithelial pattern recognition receptors (PRRs) and the possibility of these interactions in 
IL-33 release regulation. Exposure to the house dust mite allergen with proteolytic activity 
has been shown to trigger TLR4 on the pulmonary epithelial cells resulting in the production 
of IL-33 [150].  As such, the ability of allergens to trigger IL-33 release via PRRs could at 
least in part account for their allergenicity. Furthermore, given the importance of epithelial 
PRRs in promoting IL-33 release, therapeutic modulation of PRRs could also prove 
beneficial and more specific than targeting IL-33 directly.  
In addition to IL-33 release mediated by PRRs, it is interesting to speculate that active release 
of IL-33 in asthma could be regulated by structural factors involved in maintaining barrier 
integrity of the airway epithelium. As a result, defects in these proteins could lead to an 
inappropriate IL-33 release when these barriers are breached for instance by cleavage of 
tight-junction molecules by allergens with proteolytic activity such as the house dust mite 
allergen Der p 1 [226]. An interesting scenario where epithelial contacts are broken is during 
physiological airway remodeling that involves structural changes that occur during normal 
lung development. In this setting, improper IL-33 activity could turn a physiological process 
into a pathological one. In a recently published study it was found that IL-33 is spontaneously 
produced during the alveolar phase of lung development in mice, which led to an 
spontaneous accumulation of type 2 cells including ILC2s, eosinophil, mast cells and 
basophils shortly after birth [227]. HDM exposure of mice at this developmental stage further 
increased IL-33 and enhanced Th2 skewing, compared to adult mice. These results could 
explain why children under 3 years, at a time when their lungs are still developing, are at a 
high risk of developing allergic disease to inhaled allergens and how some viral infections at 
this age could exacerbate this process even further. It is tempting to speculate that an 
impaired IL-33 release at this stage could lead to altered remodeling during the 
alveolarization phase taking place in the distal lung and perhaps explain why airway 
remodeling is already observed in preschool children even in the absence of inflammation 
[103] and support the notion that airway remodeling, rather than a secondary event to 
inflammation, can evolve as a primary event initiated early in life [102].  
In study III, we performed a transcriptome analysis of the lung tissue, which showed up-
regulated expression of several genes in the combination group of IL-33 and OVA (data not 
presented in the paper) including significant up-regulation of genes for proteins that are 
involved in stress and wound repair of the barrier epithelia. It would be interesting to follow 
up on this finding and see if these genes are alternatively regulated in epithelial cells derived 
from asthma patients and their consequences for IL-33 release. Also, it would be interesting 
to investigate the expression of different PRRs on the surface of epithelial cells from asthma 
patients and the effect they have on IL-33 release in response to different triggers such as 
allergens and virus-antigens.  
Although, the focus of this thesis has been on the impact of IL-33 to exacerbate type 2 
inflammatory processes, it is now accepted that IL-33 also contributes to other immune 
responses such as TH1 and TH17 responses [228]. Interestingly, a mixed TH1 and TH17 
cytokine profile is characteristic of a subset of asthma patients with late-onset and more 
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severe forms of asthma with less reversible airway obstructions [12-14]. In the future, it 
would therefore be of interest to further understand the role of IL-33 in activing other 
immune responses in relation to different asthma subtypes. In study II we identified a 
protective role for IL-33/ST2 dependent mast cell responses on AHR development, which 
suggests that IL-33 can have different roles even in the same disease. Thus, the context in 
which IL-33 is present is important for the kind of immune response triggered. It is thus 
essential to understand under which conditions IL-33 contributes to a pathological response 
over a protective one, especially when considering IL-33 as a candidate for therapeutic 
interventions.  
In conclusion, there is a need for a better understanding of how IL33 and IL1RL1 
polymorphism translates into consequences for structure and function of their respective 
proteins. Furthermore, it is important to identify the mechanisms that regulate IL-33 release, 
including the interaction of different allergens and viral antigens with various PRRs, as well 
as factors important in maintaining epithelial integrity, to enable more specific targeting of 
this pathway. Also, the ability of IL-33 in activating other immune responses than type 2 
needs to be further characterized in relation to different asthma subtypes.  
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3 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Astma är ett samlingsnamn för olika sjukdomar i luftvägarna med gemensamma kännetecken 
som inflammation, lättirriterade luftvägar som tenderar att dra ihop sig, samt 
strukturförändringar som påverkar lungans normala funktion. Detta innebär i sin tur att 
luftflödet till lungorna kan begränsas, vilket kan ge upphov till symptom i form av hosta, 
pipande och väsande andning, samt andnöd. Symptomen återkommer i episoder och kan 
förvärras av luftvägsinfektioner, framför allt orsakade av virus, samt vid exponering för 
allergiframkallande ämnen.   
Mellan åtta och tio procent av Sveriges befolkning lider av någon form av astma. Det finns 
många olika typer av astma som orsakas av olika anledningar. Den vanligaste formen av 
astma är allergisk astma som utlöses om man kommer i kontakt med ämnen man inte tål, så 
kallade allergener, vanligtvis pollen, pälsdjur eller kvalster. Kroppens immunförsvar sätter då 
igång en inflammatorisk reaktion som på kort sikt leder till en sammandragning av 
luftvägarna och en ökad slemproduktion, men kan även i ett längre perspektiv leda till 
kroniska skador på luftvägarnas struktur med försämrad lungfunktion som följd.  
Orsaken till astma är inte klarlagd men både arv och miljö och i synnerhet samspelet mellan 
arv och miljö har stor betydelse för risken att drabbas av astma. Risken för att drabbas av 
astma ökar således om man bär på vissa gener. Det är viktigt att identifiera dessa gener och 
förstå hur de påverkar uppkomsten av astma för att kunna utveckla bättre behandlingsformer 
som i dagsläget endast behandlar symptomen och inte är tillräckligt effektiva hos ett stort 
antal individer med astma. Flera studier har under senare år visat att det finns ett samband 
mellan genen för ett signaleringsprotein, kallat IL-33, och utveckling och svårighetsgrad av 
astma. Detta tyder på att IL-33 kan utgöra en möjlig kandidat för behandling av astma, men 
först behöver man öka förståelsen för dess funktion och hur den påverkar uppkomsten och 
utvecklingen av astma. IL-33 är ett protein som finns framför allt i epitelceller som bildar en 
skyddande barriär mot omvärlden i lungan. När epitelcellerna kommer i kontakt med 
smittämnen, allergen eller andra irriterande ämnen som ger upphov till skada, släpper 
epitelcellerna ut IL-33 som i sin tur signalerar till omgivande immunceller som kan känna av 
IL-33 genom en receptor som finns på cellens yta, kallad ST2, att en skada har uppstått. Detta 
leder i sin tur till en inflammatorisk reaktion med syfte att neutralisera det främmande ämnet 
och reparera skadan. I vanliga fall är detta ett önskvärt förlopp, då kroppen reagerar med en 
inflammation för att försvara sig mot olika smittämnen, men hos individer med astma kan ett 
felaktigt utsläpp av IL-33 leda till en okontrollerad inflammatorisk reaktion som kan bli 
bestående och leda till förändringar i luftvägarnas struktur och funktion.  
Den här avhandlingen består av fyra delarbeten som syftar till att förstå hur IL-33 bidrar till 
uppkomsten och utvecklingen av astma, samt undersöker om man genom att blockera IL-33 
med ett vaccin kan förhindra att astma uppstår. För att undersöka detta har vi använt oss av 
musmodeller i alla fyra delarbeten. Musmodellerna har vissa begränsningar eftersom möss 
inte spontant utvecklar astma, men genom att utsätta dem upprepade gånger för olika allergen 
kan man framkalla ett astmaliknande tillstånd som har många av de kännetecken som finns 
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hos människan. En stor fördel med musmodeller är att man hos möss kan slå ut gener och 
således studera vilken betydelse avsaknadet av en viss gen har för sjukdomsförloppet. Det 
finns också tillgång till många verktyg som gör det möjligt att mäta viktiga faktorer som styr 
sjukdomsförloppet.  
I den första studien undersökte vi hur viktig IL-33 är för utveckling av astma genom att 
använda oss av möss som saknar ST2 (receptorn för IL-33), och därmed även möjligheten att 
svara på IL-33, samt normala möss med en fungerande ST2 receptor som kan känna av IL-
33. De här mössen utsattes sedan för kvalsterallergen i syfte att framkalla astma och vi kunde 
sedan studera hur olika reaktioner skiljde sig mellan dessa två grupper. Vi kunde bland annat 
se att möss som saknade ST2 inte utvecklade lika omfattande överkänslighet i de små 
luftvägarna som möss med ST2, medan överkänsligheten i de stora luftvägarna inte skiljde 
sig åt i de två grupperna. Detta betyder att IL-33 är viktigt för att framkalla överkänslighet 
hos de små luftvägarna men påverkar inte nämnvärt överkänsligheten hos de stora 
luftvägarna. Det är ett viktigt fynd då de små luftvägarna är inblandade i svårbehandlad astma 
och hämning av IL-33 skulle i dessa fall kunna vara en effektiv behandlingsform. Vi kunde 
även visa att den inflammatoriska reaktionen samt vävnadsförändringarna i de små 
luftvägarna dämpades hos möss som saknade ST2. Tillsammans visar dessa fynd att IL-33 är 
viktig vid uppkomsten av ett flertal reaktioner som är centrala i astmautveckling.  
I den andra studien undersökte vi hur mastceller, genom att svara på IL-33, bidrar till 
utveckling av överkänslighet och inflammation hos luftvägarna i samma musmodell som i 
den första studien. Mastceller är en typ av inflammatoriska celler som är inblandade i 
allergiska reaktioner och är således viktiga vid allergisk astma. När en person som bär på 
anlag för att utveckla allergisk astma mot exempelvis pollen kommer för första gången i 
kontakt med pollen, bildar kroppens immunförsvar så kallade IgE antikroppar som kan känna 
igen olika delar av pollen. Den här processen kallas för sensibilisering varvid mastcellen 
förbereder sig inför nästa pollenexponering genom att binda dessa antikroppar till sin yta. 
Nästa gång personen utsätts för pollen, kommer IgE antikropparna på mastcellens yta således 
känna igen pollen och reagera genom att utsöndra substanser som påverkar luftvägarnas 
förmåga att dra ihop sig och kan sätta igång många andra inflammatoriska reaktioner. Det är 
även känt att mastceller kan påverkas av IL-33, men det är inte helt klarlagt hur mastceller 
genom att känna av IL-33 bidrar till utveckling av luftvägsresponser som är centrala i 
astmautveckling. För att studera detta använde vi i den här studien möss som saknade ST2 
receptorn på endast mastceller, till skillnad från den första studien då alla celler saknade ST2, 
vilket möjliggör utredning av effekter när mastcellerna inte kan känna igen IL-33. Ett viktigt 
fynd i den här studien var att mastcellerna visade sig ha en skyddande roll i utveckling av 
luftvägsreaktivitet som svar på IL-33 och vi visar att den effekten har ett samband med 
förhöjda nivåer på ett ämne som kallas PGE2 som i tidigare studier har visat skydda 
luftvägarna från att dra ihop sig. Sammantaget, tyder resultaten från de båda studierna att IL-
33 kan ha både en skadlig och skyddande roll i utvecklingen av astma.  
I den tredje studien ville vi undersöka hur luftvägsreaktivitet, inflammation och 
vävnadsförändringar i luftvägarna påverkas om man utsätter sensibiliserade möss (möss som 
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redan bildat IgE antikroppar och är därmed rustade för återkommande exponering för 
allergenet), för det allergen de är sensibiliserade mot i kombination med IL-33. Det här 
scenariot kan ses som en förenklad modell av hur en ökad frisättning av IL-33 på grund av 
exempelvis virusinfektioner skulle kunna förvärra (exacerbera) astmasymptom hos personer 
med allergisk astma. Det visade sig att IL-33 tillsammans med allergenet förvärrade 
astmatillståndet inklusive luftvägskänsligheten, inflammationen samt luftvägsförändringar. 
Det här fyndet är av betydelse då en överdriven frisättning av IL-33 hos personer med 
allergisk astma skulle kunna förklara varför deras symptom förvärras vid exempelvis 
virusinfektioner. En annan konsekvens av fynden i den här studien är att man skulle kunna 
blockera IL-33 för att behandla exacerbationer av astma.  
I den fjärde och sista studien utvärderade vi om man med hjälp av ett vaccin mot IL-33 kan i 
likhet med vaccination mot smittämnen inducera ett immunologiskt svar som leder till att 
antikroppar som blockerar IL-33 kan bildas. Till skillnad från vacciner som riktar sig mot 
smittämnen, så medför vaccination mot ett kroppseget ämne som IL-33 en utmaning då 
kroppens immunförsvar är tränat till att inte svara på kroppsegna ämnen. Vaccinet måste 
således framställas så att immunförsvaret kan känna igen det och samtidigt inte ge upphov till 
skadliga effekter. För att uppnå detta har vi i den här studien förändrat strukturen på vaccinet 
så att kroppens immunförsvar kan bilda antikroppar mot IL-33 utan att sätta igång en skadlig 
inflammation. Det här vaccinet gavs sedan till möss innan de utsattes för kvalsterallergen och 
ytterligare påfyllnadsdos gavs efter påbörjad allergenexponering. Vi fann att IL-33 vaccinet 
både förhindrade luftvägsreaktiviteten och sänkte det inflammatoriska svaret genom att bilda 
antikroppar mot IL-33. Resultaten tyder således på att vaccinering mot IL-33 kan vara ett 
effektivt sätt att förhindra uppkomsten av astma samt användas vid behandling av 
astmaexacerbationer.  
Sammanfattningsvis ger våra studier stöd för att IL-33 har en viktig roll vid uppkomsten av 
astma och ger effekter framför allt i de små luftvägarna. Studierna tyder även på att IL-33 kan 
förvärra astmatillståndet hos en person med allergisk astma samt att behandling som 
motverkar effekten av IL-33 skulle kunna vara ett effektivt sätt att förhindra både 
uppkomsten av astma och dämpa astmaexacerbationer hos personer med astma. Samtidigt är 
det viktigt att i fortsatta studier utvärdera hur resultaten förhåller sig till människan.  
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